While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
Despite GLP-1’s incredible impact on health, Indiana is choosing to penalize people with obesity and remove access to a very effective, evidence-based treatment that improves their health.
